

**Set Name** **Query**  
side by side**Hit Count** **Set Name**  
result set

*DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; THES=ASSIGNEE;  
PLUR=YES; OP=AND*

|            |  |      |            |
|------------|--|------|------------|
| <u>L13</u> | Barry-Michael-A\$.in.  | 12   | <u>L13</u> |
| <u>L12</u> | L11 and L5   | 0    | <u>L12</u> |
| <u>L11</u> | L10 not L4   | 152  | <u>L11</u> |
| <u>L10</u> | L3 and (microprojectile or (coated adj particle))                  | 163  | <u>L10</u> |
| <u>L9</u>  | ((particle adj mediated) adj bombardment) and L3                   | 0    | <u>L9</u>  |
| <u>L8</u>  | L7 not L6  | 0    | <u>L8</u>  |
| <u>L7</u>  | L3 and L5  | 7    | <u>L7</u>  |
| <u>L6</u>  | L5 and L4  | 7    | <u>L6</u>  |
| <u>L5</u>  | (genetic or polynucleotide or (nucleic adj acid)) adj immunization | 1174 | <u>L5</u>  |
| <u>L4</u>  | L3 same (CMV or PRV)   | 146  | <u>L4</u>  |
| <u>L3</u>  | ((minimal or enhancerless) adj promoter)                           | 1159 | <u>L3</u>  |
| <u>L2</u>  | L1 and (minimal adj promoter)                                      | 0    | <u>L2</u>  |
| <u>L1</u>  | Fuller-James-T\$.in.   | 5    | <u>L1</u>  |

END OF SEARCH HISTORY

| <u>DB Name</u>           | <u>Query</u>   | <u>Hit Count</u> | <u>Set Name</u> |
|--------------------------|--|------------------|-----------------|
| USPT,JPAB,EPAB,DWPI,TDBD | L18 and plasmid  | 29               | <u>L19</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | L17 and vector   | 30               | <u>L18</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | (minimal promoter) adj sequence                                  | 32               | <u>L17</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | L15 and L12  | 3                | <u>L16</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | (coated particle)  | 7126             | <u>L15</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | L13 and ((viral or bacterial or parasite or fungal) adj antigen) | 2                | <u>L14</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | L12 and (immunization)   | 57               | <u>L13</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | L3 and vector  | 249              | <u>L12</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | L9 and ((viral or bacterial or parasite or fungal) adj pathogen) | 15               | <u>L11</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | L9 and L3  | 0                | <u>L10</u>      |
| USPT,JPAB,EPAB,DWPI,TDBD | (DNA or RNA) adj vaccine   | 276              | <u>L9</u>       |
| USPT,JPAB,EPAB,DWPI,TDBD | L3 and (genetic immunization)                                    | 0                | <u>L8</u>       |
| USPT,JPAB,EPAB,DWPI,TDBD | L6 and (CMV or PRV)  | 69               | <u>L7</u>       |
| USPT,JPAB,EPAB,DWPI,TDBD | L3 and L4  | 114              | <u>L6</u>       |
| USPT,JPAB,EPAB,DWPI,TDBD | L2 and L3  | 0                | <u>L5</u>       |
| USPT,JPAB,EPAB,DWPI,TDBD | gene therapy   | 8410             | <u>L4</u>       |
| USPT,JPAB,EPAB,DWPI,TDBD | (minimal promoter) or (enhancerless promoter)                    | 271              | <u>L3</u>       |
| USPT,JPAB,EPAB,DWPI,TDBD | (nucleic acid) adj (immunization)                                | 29               | <u>L2</u>       |
| USPT,JPAB,EPAB,DWPI,TDBD | Fuller-James-T.in.   | 5                | <u>L1</u>       |